EHNA hydrochloride

EHNA is a reversible adenosine deaminase inhibitor (IC₅₀ = 1.2 μM in human red blood cells) that also selectively inhibits the cGMP-specific phosphodiesterase (PDE2) (IC₅₀s = 0.8 and 2 μM from human and porcine myocardium, respectively, 3.5 μM in rat hepatocyte, and 5.5 μM in human platelet). Comparatively, EHNA is much less potent at inhibiting PDE1, PDE3, or PDE4 (IC₅₀s > 100 μM). EHNA has been used to evaluate cardioprotective and neuroprotective effects during ischemia, to study the role of cAMP/cGMP signaling, and to maintain pluripotency/prevent differentiation of human embryonic stem cells.

≥98%